Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Miraculins, VeraLight deal

The companies executed a final purchase agreement under which Miraculins will acquire all assets related to VeraLight's SCOUT DS technology. Miraculins

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE